Your browser doesn't support javascript.
loading
The MINT Sprint 2.0: A picture naming test for detection of naming impairments in Alzheimer's disease and in preclinical AD.
Gollan, Tamar H; Garcia, Dalia L; Stasenko, Alena; Murillo, Mayra; Kim, Chi; Galasko, Douglas; Salmon, David P.
Afiliación
  • Gollan TH; Department of Psychiatry, University of California, San Diego, La Jolla, California, USA.
  • Garcia DL; Joint Doctoral Program in Language and Communicative Disorders, San Diego State University/University of California, San Diego, La Jolla, California, USA.
  • Stasenko A; Department of Psychiatry, University of California, San Diego, La Jolla, California, USA.
  • Murillo M; Department of Psychiatry, University of California, San Diego, La Jolla, California, USA.
  • Kim C; Department of Neurosciences, University of California, San Diego and Shiley-Marcos Alzheimer's Disease Research Center, La Jolla, California, USA.
  • Galasko D; Department of Neurosciences, University of California, San Diego and Shiley-Marcos Alzheimer's Disease Research Center, La Jolla, California, USA.
  • Salmon DP; Department of Neurosciences, University of California, San Diego and Shiley-Marcos Alzheimer's Disease Research Center, La Jolla, California, USA.
Alzheimers Dement ; 20(1): 112-123, 2024 Jan.
Article en En | MEDLINE | ID: mdl-37464962
INTRODUCTION: Evidence on the onset of naming deficits in Alzheimer's disease (AD) is mixed. Some studies showed an early decline, but others did not. The present study introduces evidence from a novel naming test. METHODS: Cognitively normal (n = 138), mild cognitive impairment (MCI; n = 21), and Alzheimer's disease (AD; n = 31) groups completed an expanded Multilingual Naming Test with a time-pressured administration procedure (MINT Sprint 2.0). Cerebrospinal fluid biomarkers classified participants as true controls (n = 61) or preclinical AD (n = 26). RESULTS: Total correct MINT Sprint 2.0 scores exhibited good sensitivity and specificity (>0.85) for discriminating true controls from cognitively impaired (MCI/AD) groups and showed significant differences between true controls and preclinical AD groups. Time measurement did not improve classification, but percent resolved scores exhibited promise as an independent AD marker. DISCUSSION: Naming deficits can be detected in the earliest stages of AD with tests and procedures designed for this purpose.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Multilingüismo / Enfermedad de Alzheimer / Disfunción Cognitiva Tipo de estudio: Diagnostic_studies Límite: Humans Idioma: En Revista: Alzheimers Dement Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Multilingüismo / Enfermedad de Alzheimer / Disfunción Cognitiva Tipo de estudio: Diagnostic_studies Límite: Humans Idioma: En Revista: Alzheimers Dement Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos